JAK-STAT Pathway Activation in Malignant and Non-Malignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

The identification of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN) led to the clinical development of JAK kinase inhibitors, including ruxolitinib. Ruxolitinib reduces splenomegaly and systemic symptoms in myelofibrosis (MF) and improves overall survival; however the mechan...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Discov
Huvudupphovsmän: Kleppe, Maria, Kwak, Minsuk, Koppikar, Priya, Riester, Markus, Keller, Matthew, Bastian, Lennart, Hricik, Todd, Bhagwat, Neha, McKenney, Anna Sophia, Papalexi, Efthymia, Abdel-Wahab, Omar, Rampal, Raajit, Marubayashi, Sachie, Chen, Jonathan J., Romanet, Vincent, Fridman, Jordan S., Bromberg, Jacqueline, Teruya-Feldstein, Julie, Murakami, Masato, Radimerski, Thomas, Michor, Franziska, Fan, Rong, Levine, Ross L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4355105/
https://ncbi.nlm.nih.gov/pubmed/25572172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0736
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk